Payment overview · 2025
General Payments
$125.29
6 reported records · 3 companies
Healthcare provider profile · identity verified
Steven Mark Brewer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · THOMASVILLE, GA · NPI 1952377905
Verified facts
What the public records show
CMS Open Payments records show Steven Mark Brewer, MD received $125.29 in general payments during 2025 across 6 reported records.
GlaxoSmithKline, LLC. accounted for 70.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.67 | 70.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.36 | 14.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.26 | 14.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.29 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.67 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
89 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
49 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 727 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 101 |
| Gabapentin | Gabapentin | 424 | 82 |
| Omeprazole | Omeprazole | 384 | 100 |
| Lorazepam | Lorazepam | 356 | 69 |
| Furosemide | Furosemide | 344 | 91 |
| Losartan Potassium | Losartan Potassium | 330 | 91 |
| Prednisone | Prednisone | 307 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 83 |
| Eliquis | Apixaban | 298 | 45 |
| Lisinopril | Lisinopril | 288 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 68 |
| Sertraline Hcl | Sertraline Hcl | 270 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 63 |
| Potassium Chloride | Potassium Chloride | 211 | 47 |
| Clonazepam | Clonazepam | 208 | 39 |
| Alendronate Sodium | Alendronate Sodium | 191 | 41 |
| Meloxicam | Meloxicam | 190 | 57 |
| Tramadol Hcl | Tramadol Hcl | 190 | 66 |
| Metformin Hcl | Metformin Hcl | 183 | 50 |
| Simvastatin | Simvastatin | 176 | 48 |
| Alprazolam | Alprazolam | 169 | 37 |
| Allopurinol | Allopurinol | 162 | 42 |
| Trazodone Hcl | Trazodone Hcl | 162 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 41 |
| Ezetimibe | Ezetimibe | 139 | 32 |
| Atenolol | Atenolol | 136 | 30 |
| Mirtazapine | Mirtazapine | 135 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 124 | 78 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 30 |
| Montelukast Sodium | Montelukast Sodium | 117 | 29 |
| Doxepin Hcl | Doxepin Hcl | 116 | 16 |
| Glimepiride | Glimepiride | 110 | 26 |
| Farxiga | Dapagliflozin Propanediol | 106 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 102 | 21 |
| Repatha Sureclick | Evolocumab | 95 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 19 |
| Estradiol | Estradiol | 90 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 89 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 88 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 83 | 19 |
| Celecoxib | Celecoxib | 80 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 23 |
| Meclizine Hcl | Meclizine Hcl | 77 | 25 |
| Donepezil Hcl | Donepezil Hcl | 74 | 14 |
| Ozempic | Semaglutide | 74 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 19 |
| Bupropion Xl | Bupropion Hcl | 70 | 17 |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Azithromycin | Azithromycin | 69 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 20 |
| Nifedipine Er | Nifedipine | 62 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 21 |
| Digoxin | Digoxin | 59 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Memantine Hcl | Memantine Hcl | 58 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Levofloxacin | Levofloxacin | 55 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 43 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Finasteride | Finasteride | 50 | 16 |
| Famotidine | Famotidine | 49 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 43 |
| Lansoprazole | Lansoprazole | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Nystatin | Nystatin | 47 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 43 | 22 |
| Methylprednisolone | Methylprednisolone | 41 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Metolazone | Metolazone | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 22 |
| Clonidine Hcl | Clonidine Hcl | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Linzess | Linaclotide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Fentanyl | Fentanyl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 14 |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Diazepam | Diazepam | 20 | 14 |
| Fluconazole | Fluconazole | 20 | 12 |
| Glipizide | Glipizide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 14 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Colchicine | Colchicine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.29 · 6 records | GlaxoSmithKline, LLC. | Fluad, Flucelvax, Ozempic, Rybelsus, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error